Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Ariad begins phase II trial of ponatinib in chronic myeloid leukemia

Sep. 14, 2010

Cyclacel and FDA agree on a special protocol assessment for phase III sapacitabine trial

Sep. 14, 2010

New dual mTOR/PI3K-alpha inhibitor PF-04979064 may advance to clinic as anticancer agent

Sep. 14, 2010

FDA approves new 500-mg dose of Faslodex

Sep. 13, 2010

Debiopharm and Aurigene nominate Debio-0617 as development candidate

Sep. 13, 2010

Regeneron provides update on trials of aflibercept in metastatic colorectal cancer

Sep. 13, 2010

Bayer Schering claims new hepatocyte growth factor receptor inhibitors

Sep. 13, 2010

Phase III COU-AA-301 trial of abiraterone/prednisone is unblinded due to efficacy

Sep. 10, 2010

Tragara Pharma begins phase I TG-02 trial in hematological malignancies

Sep. 10, 2010

Boehringer Ingelheim presents new C-raf inhibitors

Sep. 10, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...